MacroGenics seeks FDA approval for breast cancer treatment
MacroGenics Inc. (NASDAQ: MGNX) is closing in on the finish line to earn regulatory approval for its first product, a breast cancer therapy candidate.
The Rockville biotech has submitted its Biologics License Application to the Food and Drug Administration for margetuximab, which targets “HER2” — a gene that can fuel cancer cell growth. FDA approval would give MacroGenics the final go-ahead to commercialize the product and treat patients w ith metastatic HER2-positive breast cancer along with…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Food and Drug Administration (FDA) | Genetics | Health Management | HER2 | Pharmaceuticals